Achieve Life Sciences Inc. Common Shares (QUIT)
QUIT trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2019-12-31, https://www.sec.gov/Archives/edgar/data/949858/000156459020010642/0001564590-20-010642-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2019-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | QUIT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000949858 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | DE |
Financials · 2019
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$16.4M |
| Operating income | Not in SEC XBRL data |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $16.7M |
| Total assets | $21.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $59.7M cash; operating cash flow -$11.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 110,034,457 (2026-11-10); 53,233,988 a year earlier; 21,165,760 three years earlier. | Cover page 2026-11-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-08-14 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Vancouver, Canada | PCAOB Form AP 2026-04-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $175K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$12.1M | -$8.4M | $59.7M | $13.0M | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | Not filed | -$74.8M | -$10.8M | $48.0M | $14.9M | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2026 2026-03-31 | Not filed | -$10.2M | -$6.9M | $28.1M | $14.9M | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2025 2025-12-31 | Not filed | -$14.7M | -$18.0M | $20.9M | $14.9M | Needs four quarters | 10-K 2026-03-24 |
| Q3 2025 2025-09-30 | Not filed | -$14.4M | -$11.3M | $31.9M | $9.9M | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$12.7M | -$9.1M | $51.9M | $9.9M | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2025 2025-03-31 | Not filed | -$12.8M | -$11.1M | $13.0M | $9.9M | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2024 2024-12-31 | Not filed | -$12.4M | -$9.2M | $12.8M | $9.8M | Needs four quarters | 10-K 2026-03-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-14 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEF 14A | 2026-06-08 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.0% |
| 1 month | -9.7% |
| 3 months | -12.8% |
| Year to date | +27.2% |
| 1 year | +38.0% |
| From 52-week high | -25.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| QDEL | QuidelOrtho Corporation | $10.21 | -4.93% | $700.5M |
| NNNN | Anbio Biotechnology | $3.88 | +1.57% | $558.3M |
| MYGN | Myriad Genetics Inc. | $5.57 | -1.59% | $534.3M |
| TKNO | Alpha Teknova Inc. | $7.77 | -5.36% | $488.8M |
| NTLA | Intellia Therapeutics Inc. | $9.86 | +1.65% | $1.4B |
| CLDX | Celldex Therapeutics Inc. | $28.59 | -0.83% | $2.2B |
| NEOG | Neogen Corporation | $10.88 | -3.12% | $2.4B |
| ICCC | ImmuCell Corporation | $11.42 | +6.23% | $103.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier